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Abstract 22 
Introduction: A novel Pan-Leishmania LAMP assay was developed for diagnosis of Cutaneous and 23 
Visceral Leishmaniasis (CL & VL) which can be used in near-patient settings.  24 
Methods: Primers were designed on the 18S rDNA and the conserved region of minicircle kDNA 25 
selected on the basis of high copy number. LAMP assays were evaluated for CL in a prospective 26 
cohort trial of 105 patients in South-West Colombia. Lesion swab samples from CL suspects were 27 
collected and tested using LAMP and compared to a composite reference of microscopy AND/OR 28 
culture to calculate diagnostic accuracy.  LAMP assays were tested on 50 VL suspected patients from 29 
Ethiopia, including whole blood, peripheral blood mononuclear cells, and buffy coat. Diagnostic 30 
accuracy was calculated against a reference standard of microscopy of splenic or bone marrow 31 
aspirates. To calculate analytical specificity 100 clinical samples and isolates with fever causing 32 
pathogens including malaria, arboviruses and bacterial infections were tested.  33 
Results & Conclusions: The LAMP assay had a sensitivity of 95% (95% CI: 87.2% - 98.5 %) and a 34 
specificity of 86% (95% CI: 67.3% -95.9 %) for the diagnosis of CL. On VL suspects the sensitivity was 35 
92% (95% CI: 74.9 – 99.1%) and specificity of 100% (95% CI: 85.8-100%) in whole blood.  For CL, 36 
LAMP is a sensitive tool for diagnosis and requires less equipment, time and expertise than 37 
alternative CL diagnostics. For VL, LAMP is sensitive using a minimally invasive sample as compared 38 
to the gold standard. The analytical specificity was 100%.  39 
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Introduction: 40 
Infection with Leishmania parasites causes a spectrum of diseases from self-healing skin ulcers, 41 
cutaneous leishmaniasis (CL), to the potentially fatal form, visceral leishmaniasis (VL) affecting 42 
internal organs, in particular spleen, liver, bone marrow and lymph nodes. Accurate and opportune 43 
laboratory diagnosis followed by appropriate treatment is crucial in patient management, and to 44 
decrease transmission (1). Parasitological confirmation by microscopy of biopsies, sometimes in 45 
combination with culture techniques, remains the reference standard laboratory diagnosis for both 46 
VL and CL. For VL serological diagnostics are available in the form of rapid diagnostics tests (RDTs) 47 
and ELISAs optimally based on rK39 (2, 3), the Direct Agglutination Test (DAT)(4), and 48 
immunofluorescent antibody tests (IFA/IFAT). However, due to poor specificity, these tests are only 49 
recommended for use after prolonged fever, most commonly taken as more than 14 days of fever 50 
(3).  No alternative serological diagnostic test exists for CL due to low concentrations of circulating 51 
antibodies; as regards molecular tools, several diagnostic protocols have been validated for CL but 52 
no reference standards are currently available. 53 
Reference standard diagnostic tests suffer from challenges; microscopy can be poorly sensitive, lack 54 
standardisation of tissue collection, requires quality control and invasive sample types. The rK39 55 
RDTs lack specificity and also sensitivity in certain regions, and culture methods require time, 56 
expertise and considerable infrastructure.  57 
A recent advance in nucleic acid-based diagnostics has been the development of loop-mediated 58 
isothermal amplification (LAMP) of DNA. LAMP diagnostic kits have been developed for a variety of 59 
infectious diseases, including tuberculosis (5, 6), human African trypanosomiasis (HAT) (7) and 60 
malaria (8, 9). This nucleic acid amplification technique (NAAT) uses only one enzyme (Bst DNA 61 
polymerase) and is able to amplify large amounts of DNA within 40 minutes by the intricate design of 62 
primers and auto-strand displacement DNA synthesis. A thermocycler is not required because the 63 
enzyme works under isothermal conditions, reagents are dried-down with no requirement of a cold-64 
 o
n
 M
ay 11, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://jcm.asm.org/
D
ow
nloaded from
 
4 
 
chain. Results can be read visually, and there is no post-amplification handling or processing. This 65 
makes LAMP a powerful diagnostic test for disease endemic settings, bringing molecular diagnostics 66 
closer to the patient. 67 
Recent modelling data for VL diagnostics shows that early diagnosis and treatment of patients has 68 
the potential to greatly reduce transmission of disease in elimination areas (1). Diagnostics that can 69 
specifically identify and allow treatment of patients earlier than is currently possible have the 70 
potential to reduce transmission.  71 
There have been previous attempts to develop a LAMP test for Leishmaniasis (10, 11). However, 72 
these were in-house assays rather than diagnostic kits, and should not be considered for quality-73 
controlled, standardised use. In addition, the design of some LAMP primer sets is geographically 74 
focused and therefore not suitable for all Leishmania endemic areas (11). Here we describe the 75 
development of a novel LAMP assay, with the advantages of quality control and standardisation that 76 
comes with product development.  Data collected during development of the assay from cohorts of 77 
suspected CL patients in Colombia, and suspected VL patients from Ethiopia, are presented.   78 
Material and Methods: 79 
Target selection: A combination of literature searches and sequence alignment identified potential 80 
target genes conserved within the genus Leishmania that had low homology (<80%) to other targets, 81 
including the Trypansoma as the nearest taxonomic pathogen to Leishmania, and human DNA. The 82 
Leishmania were represented by the five reference genomes of L. major 83 
MHOM/IL/1981/Friedlin(12), L. braziliensis MHOM/BR/1975/M2904 (13), L. mexicana 84 
MHOM/GT/2001/U1103cl25 (14), L. donovani MHOM/NP/2003/BPK282/0cl4 (15) and L. infantum 85 
(JPCM5) MCAN/ES/1998/LLM-87 (13). To exclude targets that could be amplified due to 86 
trypanosomiasis, the Trypansoma were represented by T. cruzi CL Brenner (TcVI) (16), T. cruzi Sylvio 87 
×10/1 (TcI) (17), T. vivax Y486 (18), T. brucei TREU927 (19), and T. congolense IL3000 (20). Sequence 88 
conversation and suitability as a LAMP target were assessed using genome-wide sequence alignment 89 
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with MAVID (21) following construction of an orthology map with Mercator (22), which identified 90 
CDS regions with Genscan, and measured orthology with BLAT and MUMmer. Sequences totalling 21 91 
Mb in length were present in all five Leishmania (average ~32 Mb) and absent in all five Trypansoma. 92 
14,030 candidate LAMP targets of >200 bp were identified - these spanned 7,942 Kb of sequence. 93 
Gene length, GC content and in silico copy number were evaluated using read information with 94 
Samtools v0.1.11 (23). Gene length, GC content and in silico copy number were evaluated using read 95 
information with Samtools v0.1.11 (23) and a priority list of targets for primer design was made.  96 
Further sequence alignment showed only 18 substitutions at the 2,190 bp 18S rDNA gene using 97 
GenBank PopSet 254847845 (24) across nine Leishmania species (the five above plus L. amazonensis, 98 
L. guyanensis, L. panamensis and L. tropica). The 3’ end (1954-2190) of the 18S rDNA gene showed 99 
some homology to Trypanosoma.  100 
Copy-number calculation: In order to rank genes in priority for LAMP primer design, the copy 101 
number of each potential target was experimentally calculated as follows. Promastigotes were 102 
cultivated in RPMI-1640 culture medium containing 10% Fetal calf serum, at 27°C. DNA from 8 103 
Leishmania species were extracted using the DNeasy extraction kit (Qiagen) at the log phase. For the 104 
purposes of this study we refer to VL causing species (L. donovani and L. infantum) and CL causing 105 
species (L. tropica, L. major, L. braziliensis, L. mexicana, L. panamensis, L. guyanensis).  Alignments 106 
were made using T coffee software (www.tcoffee.crg.cat/) for all target genes except the kDNA 107 
where existing primer sets from Cavalcanti et al. (25) were used. Each target gene was amplified 108 
with HotStar Taq polymerase, using the following protocol: 94°C 10min., followed by 40 cycles of 109 
94°C for 30s., 52°C, 55°C or 58°C for 30s and 72°C for 30S, and final hold of 72°C for 10 min.  110 
Resultant fragments were cloned as single copy vectors using TOPO TA cloning kit (Invitrogen). 111 
Colony PCR was used to select colonies containing the insert, and transformants were cultured in LB 112 
medium containing ampicillin (50µg/mL). DNA was extracted using the Qiagen plasmid midi kit, and 113 
DNA digestion was performed for 2 hours at 37°C with EcoRI and HINDIII/XBA restriction enzymes. A 114 
sybr green qPCR was performed for each target gene: 95°C 5 min. followed by 40 cycles of 95°C for 115 
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10s and 60°C for 40s. A 10 fold dilution series of vector DNA was used as a standard curve, where the 116 
vector was known to contain a single copy of the target gene, and the weight of the vector was 117 
known. Additionally, a 5 fold dilution series of promastigote DNA was included, whereby the weight 118 
of the whole genome was known (14). The DNA concentrations of the vector and genomic DNA were 119 
determined using the ThermoScientific nanodrop 1000 spectrophotometer. The Cycle threshold (Ct) 120 
of genomic DNA was compared with the Ct of vector DNA and copy number was calculated by the 121 
standard formula:  122 
Copy number =   Known Concentration of Vector DNA (ng/µl)/Vector weight (ng)   123 
  Concentration genomic DNA (ng/ul) calculated by qPCR/Genome weight (ng)  124 
The gene 7SL, was used as a control as a known single-copy gene (26).   125 
Primer design: Genes 18S rDNA, Histone H3 and kDNA (Table 1) were chosen for primer design 126 
based on their high copy-number. PrimerExplorer version 4.0 software 127 
http://primerexplorer.jp/elamp4.0.0 was used to design LAMP primers on all 3 targets. Targets with 128 
highest copy number were multiplexed to optimise sensitivity.  129 
Limit of Detection: In order to determine the limit of detection (LOD) of each of the prototype LAMP 130 
primer sets, serial dilutions of DNA from 8 species (see above) from different geographical areas, 131 
including Asia and Africa were tested; this included 2 strains for CL causing species and 4 strains for 132 
VL causing species, L. infantum and L. donovani. Cultured promastigotes of Leishmania species were 133 
prepared, and DNA extracted using phenol/chloroform extraction method.  A 10-fold dilution series 134 
was tested from 1,000 parasites per µl to 0.001 p/µl. To ensure there was no cross reactivity of the 135 
LAMP primer sets they were tested with serial dilutions of DNA from Trypanosoma brucei, T. cruzi, 136 
Plasmodium falciparum, human cell lines THP1 and U937, salmon sperm, human whole blood and 137 
buffy coat.   138 
Bank of pathogen samples: In order to ensure the specificity of the LAMP assay, 50 clinical samples 139 
or cultured isolates were tested. These included high, medium and low concentration samples of 140 
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Plasmodium falciparum, P. vivax, Trypanosome brucei brucei, Trypanosoma cruzi, Giardia lamblia, 141 
Cryptosporidium parvum; and 50 isolates of high, medium and low concentration dengue, 142 
chikungunya, Zika and bacterial species including Escherichia coli and Klebsiella pneumoniae. 143 
Cutaneous Leishmaniasis clinical samples: A prospective collection of samples from suspected CL 144 
patients from CIDEIM, Colombia (27) was used to estimate the diagnostic sensitivity of the 145 
developed prototype multiplex LAMP kit (kDNA plus 18S rDNA primers).  One lesion swab sample 146 
(Isohelix DNA buccal swabs, SK-1S) was taken per suspected patient by gently rubbing a swab over 147 
the ulcer ~10 times, and then stored at -20°C. Qiagen DNAeasy blood and tissue kit (Qiagen, USA) 148 
was used to extract DNA according to manufacturer’s instructions and eluted in 50µl distilled water. 149 
Diagnostic performance of LAMP was compared with a composite reference standard of microscopy 150 
AND/OR culture positivity. Briefly, two slides with three lesion smears on each slide were 151 
microscopically examined for amastigotes; parasite isolation in semisolid culture medium was 152 
attempted from 4 independent lesion aspirates from each participant. Parasite isolation was traced 153 
for a maximum of one-month post-inoculation.   154 
Ethics: This study was approved and monitored by the Centro Internacional de Entrenamiento e 155 
Investigaciones Médicas institutional review board for ethical conduct of research involving human 156 
subjects 157 
Visceral Leishmaniasis clinical samples: Blood was collected from 50 VL suspected patients from 158 
University of Gondar Hospital, Amhara Regional State, Northern Ethiopia, in 2013. In order to 159 
determine the optimal extraction method with respect to parasite numbers, we compared the 160 
isolation of peripheral blood mononuclear cells (PBMC) with buffy coat, and with whole blood stored 161 
in heparin tubes from the same patient samples. PBMC were isolated by slowly layering two ml 162 
heparin blood on top of an equal volume of Histopaque (Sigma, Aldrich), the sample was centrifuged 163 
for 30 minutes at 2000 rpm. The PBMC fraction was removed and suspended in 600 µl PBS, and once 164 
again centrifuged for 1 minute at 8000 rpm. The cells were re-suspended in 180µl PBS. The buffy 165 
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coat fraction was isolated by centrifuging two ml heparin blood for 5 minutes at 8,000 rpm. The 166 
buffy coat fraction was removed and suspended in PBS to a total volume of 180 µl. All PBMC, buffy 167 
coat and plain heparin blood samples (180 µl volumes) were mixed with an equal volume of AS1 168 
buffer (Qiagen). DNA was extracted with Qiagen mini blood and tissue extraction kit according to 169 
protocol and resultant samples stored at -20°C. LAMP and qPCR were compared to microscopy of 170 
either bone-marrow or spleen-aspirate as the gold standard. 171 
Ethics: This study was approved and monitored by the University of Gondar Institutional Review 172 
Board, Ethiopia, (Ref R/C/S/V/P/05/664/2013). Written informed consent was obtained from 173 
patients for the use of their specimens in the study.  174 
Molecular methods:  175 
LAMP: LAMP (Eiken Chemical, Japan) was performed as per manufacturer’s instructions. 3µl 176 
extracted DNA was added to a LAMP tube plus 27µl water. Tubes were turned upside down for 2 177 
minutes to release the dried-down reagents in the cap of the tube. Samples were briefly centrifuged 178 
and then placed in a real-time turbidimeter (Eiken) at 65°C for 40 minutes, and then 80°C for 2 179 
minutes. A LAMP reaction was considered positive for Leishmania if fluorescence was observed 180 
visually and if a positive reaction was observed in the turbidimeter. Discrepancies between these 181 
two methods were recorded.  182 
qPCR: qPCR was performed on DNA extracted from swab samples as described in Adams et al. 2014, 183 
based on amplification of the 18S rDNA gene for amplification of CL (27).  kDNA qPCR was performed 184 
on all VL patient samples (N=50). 1.2 µL of DNA was added to 11.3 µL amplification mix containing 185 
6.25 μL iQ Supermix (Bio-Rad, cat.no. 170-8862),0.25 μM forward primer kDNA(5’-186 
TCCCAAACTTTTCTGGTCCT-3’), 0.25 μM reverse primer kDNA(5’-TTACACCAACCCCCAGTTTC-3’), 0.12 187 
μM probe kDNA (5’ FAM- TTCTGCGAAAACCGAAAAATGGGTGC-BHQ 3’). The qPCR protocol (Bio-Rad 188 
CFX-96) was as follows: 5 minutes at 95°C followed by 40 cycles of 10 s at 95°C and 40 s at 54°C.  189 
 o
n
 M
ay 11, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://jcm.asm.org/
D
ow
nloaded from
 
9 
 
qPCR was used in this programme as a comparator molecular method to LAMP to understand results 190 
fully. Diagnostic accuracy of data, including sensitivity and specificity, was calculated for LAMP and 191 
qPCR. This study followed the STAARD guidelines, including blinding of index and reference 192 
diagnostic tests.  193 
 194 
Results: 195 
Target selection: The relative copy number of nine different target genes was calculated for the 8 196 
Leishmania species tested, with an average across two strains. Results are shown for the highest 197 
copy number targets in Table 1, relative to the known single copy target of the 7SL gene.   198 
Prototype primer sets: Primer design was attempted on 3 target genes, the 18S rDNA and the 199 
Histone 3 for pan-Leishmania assays and the kDNA for a VL specific assay. Each primer set was 200 
tested for the Limit of Detection (LOD) using a real-time LAMP turbidimeter. The kDNA had the 201 
lowest LOD at 0.0001 p/µl on L. donovani and L. infantum, and no amplification with other CL 202 
causing Leishmania species. The 18S rDNA had the next lowest LOD at 0.01-0.001 p/µl. The Histone 203 
LAMP primers had a similar LOD to the 18s rDNA at 0.01 p/µl, but could not amplify all L. guyanensis 204 
and L. braziliensis, indicating low sequence homology to some South American strains. The targets 205 
18S rDNA and kDNA, were multiplexed to optimise sensitivity for detecting VL, and ability to detect 206 
all Leishmania species that cause CL; LOD was not affected by multiplexing.  All testing of primer sets 207 
was performed using the dried-down LAMP assay developed by Eiken.  No cross-reaction was 208 
observed with serial dilutions of DNA from T. brucei, T. cruzi, P. falciparum, salmon sperm, human 209 
cell lines THP1 and U937, human whole blood and buffy coat.  210 
Bank of pathogen samples: Of 100 clinical samples and cultured isolates from different pathogens, 211 
none were positive with the Leish LAMP kit, showing an analytical specificity of 100%. 212 
Cutaneous Leishmaniasis samples: 105 clinical suspects were enrolled. A complete description of 213 
demographic and clinical characteristics of study participants and Leishmania species is reported in 214 
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Adams et al., 2014. Parasites were isolated and identified in 64% of the participants; L. panamensis 215 
predominated overall, with representation from the Viannia and Leishmania subgenera. Compared 216 
to the reference standard of microscopy AND/OR culture, LAMP (kDNA + 18S rDNA) was 95% 217 
sensitive (95% CI: 87.22 % to 98.53 %) and 86% specific (95% CI: 67.32 % to 95.88 %). This compared 218 
well with qPCR data on the same samples, which showed a sensitivity of 97% (95% CI: 91%-100%) 219 
and specificity of 84% (95% CI: 64%-95%). 220 
Visceral Leishmania samples: In this study, 50 VL suspects were enrolled, of which 26 were positive 221 
for VL by microscopy of the splenic (n=19 positive) or bone marrow (n=7 positive) aspirates. Of the 222 
26 VL positive individuals 27% (n=7) were also positive for HIV.  223 
Parasite load was quantified by qPCR in order to compare the extraction efficiency of the different 224 
sample types (whole blood, buffy coat and PBMCs). Of the 26 VL parasitologically positive 225 
individuals, the highest parasite load as determined by ct threshold on kDNA qPCR, was found in 226 
whole blood (n=19) followed by buffy-coat (n=5) and PBMC (n=1) of 25 qPCR positive individuals.  227 
On VL suspects from Ethiopia, the sensitivity from whole blood was 92% (95% CI: 74.9 – 99.1%) and 228 
specificity of 100% (95% CI: 85.8-100%). The sensitivity of kDNA qPCR was 96% (95% CI: 80.1-99.9%) 229 
and specificity of 92% (95% CI: 73-99%). The sensitivity of both tests was the same on buffy coat 230 
samples but this decreased to 89% in PBMCs samples (see Table 2). The specificity was highest on 231 
LAMP from whole blood at 100% dropping to 96% on other sample types (see Table 2). qPCR had a 232 
specificity of between 92% and 95% depending on sample type. However, sample numbers are 233 
limited and confidence intervals overlap. Notably, all HIV positive patients (n=7) were positive for 234 
both qPCR and LAMP in all sample types.  235 
 236 
No discrepancies were reported between the visual analysis of the LAMP tubes for fluorescence and 237 
the real-time turbidimeter data.  238 
Discussion:  239 
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This study presents data on the development of a LAMP diagnostic kit capable of detecting both VL 240 
and CL. Target genes were chosen based on high copy number and conservation across multiple 241 
strains and species of Leishmania across geographic areas. 18S rDNA and kDNA primer sets were 242 
multiplexed to ensure a sensitive reaction for VL (kDNA) and the capability to detect all species 243 
causing CL (18S rDNA). Since the differential diagnosis and sample types of VL and CL does not 244 
overlap, the combination of primers is considered appropriate. Testing was performed on 245 
geographically distinct strains and species of Leishmania to ensure production of a robust and 246 
reliable test. The multiplex LAMP was highly sensitive and specific, with a limit of detection between 247 
0.01-0.001 parasites per µl for CL causing species, and 0.0001 parasites per µl for VL causing species 248 
on purified DNA.  LAMP was 100% specific when tested on a range of fever causing organisms with 249 
overlapping epidemiology as Leishmania; this included, bacterial infections, malaria, arboviruses and 250 
other protozoan infections. LAMP was taken forward for testing on prospective clinical sample 251 
collections. In a cohort of suspected CL patients from South West Colombia LAMP was 95% sensitive 252 
(95% CI: 87.2%-98.5%) and 86% specific (95% CI: 67.3%-95.9 %). In a study on 50 suspected VL 253 
patients the LAMP showed a sensitivity of 92.3% (95% CI: 74.9%-99.1%) and a specificity of 100% 254 
(95% CI: 86.7%-100%) on whole blood. Due to the reduced number of sample handling steps and 255 
reduced ct values, the whole blood sample type is preferable for VL compared with PBMCs and buffy 256 
coat.   257 
For CL samples, the LAMP test showed overlapping confidence intervals with qPCR, and was more 258 
sensitive than culture and microscopy alone. The lower specificity of both qPCR and LAMP may 259 
represent patients not detected by the composite reference standard, as no perfect gold standard 260 
test for CL exists. Multiple studies including (27, 28), have concluded that the molecular tools are 261 
more sensitive for diagnosing CL, and therefore, false positives in molecular tools may be considered 262 
truly positive patients. Follow-up studies of participants needs to be conducted to determine 263 
whether this is the case. Swab sampling on lesions was an appropriate collection method, although 264 
this would need adaptation to areas where non-ulcerated lesions of CL are prevalent.  265 
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In VL samples, LAMP performed on DNA extracted from whole blood showed good sensitivity 266 
compared to microscopy of highly invasive biopsy samples. The kDNA qPCR was only slightly more 267 
sensitive (96%) as compared to LAMP (92%) in the Ethiopian collection. The extraction of DNA from 268 
whole blood resulted in a higher parasite load in qPCR than either processing PBMC or buffy-coat in 269 
spite of the fact that, for the latter two methods, ten times more blood was used for extraction (200 270 
µl vs 2 ml). Using plain heparin blood for extraction is favourable since a smaller volume of blood is 271 
required, and the processing of this sample type requires fewer handling steps. Microscopic 272 
examination on bone-marrow or spleen aspirates will remain the gold standard because parasite 273 
numbers are high in these sample types. However, based on these results, LAMP could potentially 274 
be used to confirm infection in the majority of patients, and then aspiration performed in those that 275 
are LAMP negative but who remain VL suspects. This would circumvent aspiration in the majority of 276 
patients. Also in areas where it is not possible to take biopsy samples due to lack of appropriate 277 
medical facilities LAMP may be used as to confirm infection.  278 
Modelling studies have suggested the use of highly specific diagnostic tools for the detection of VL in 279 
elimination zones (1). This would enable treatment of cases earlier than is currently possible in the 280 
diagnostic algorithm. Results for VL suspects in Ethiopia show a high specificity of 100% (95% 281 
CI: 85.8-100%), intimating that LAMP may be a suitable tool for this purpose.  282 
LAMP has been developed as a platform diagnostic tool and is now available for malaria, 283 
tuberculosis and HAT, as well as a range of viral and bacterial infections. Here, this powerful 284 
diagnostic tool has now been designed for Leishmaniasis, and tested on Leishmania suspects from 285 
Colombia and Ethiopia. LAMP is simple and does not require expensive equipment and therefore can 286 
be used in basic laboratory facilities with minimal DNA extraction facilities.  Further development 287 
work and evaluation data is required. For CL it would be useful to follow up patients with (false) 288 
positive LAMP reactions to see if they become positive with the gold standard. As alternative 289 
diagnostics exist for VL, the use of LAMP may be to confirm suspected patients in areas with poor 290 
infrastructure, and before 14 days of fever has passed.   291 
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Tables: 408 
Table 1. Three highest copy number targets with low homology to other related pathogens. Copy 409 
number taken from literature and experimentally.  410 
 411 
Target Copy number Literature Copy number 
experimental 
Kinetoplast DNA (visceral 
leishmaniasis) 
> 10,000 7,500-22,500
18S ribosomal DNA  20-200 300-2200
Histone H3 X 80-380
7SL RNA 1 1
 412 
 413 
Table 2. Correlation between Microscopy, PCR and LAMP on blood, PBMC and buffy-coat from 50 VL 414 
suspected patients from Ethiopia, Gondar teaching hospital. TP = True Positive, FN = False Negative, 415 
TN = True Negative, FP = False Positive. PBMC = Peripheral Blood Mononuclear Cells. 95% CI = 95% 416 
Confidence Intervals.   417 
 418 
Sample Whole Blood PBMCs Buffy-coat 
Test PCR (95% 
CI) 
LAMP (95% 
CI) 
PCR (95% 
CI) 
LAMP 
(95% CI) 
PCR (95% 
CI) 
LAMP (95% 
CI) 
TP 25 24 25 23 25 24 
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FN 1 2 1 3 1 2 
TN 22 24 23 23 23 23 
FP  2 0 1 1 1 1 
Sensitivity  96.1% 
(80.1-99.9) 
92.3% 
(74.9-99.1) 
96.1% 
(80.1-99.9) 
88.5% 
(69.9-97.6) 
96.1% (80.1-
99.9) 
92.3% (74.9-
99.1) 
Specificity  91.7% (73 - 
99) 
100% 
(86.7-100) 
95.8% 
(78.9-99.9) 
95.8% 
(78.9-99.9) 
95.8% (78.9-
99.9) 
95.8% (78.9-
99.9) 
 419 
 420 
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